X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ASTRAZENECA PHARMA with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs MYLAN (US) - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   MYLAN
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
MYLAN
Dec-14
ASTRAZENECA PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,2853,867-   
Low Rs6342,725-   
Sales per share (Unadj.) Rs189.61,324.0-  
Earnings per share (Unadj.) Rs-0.2159.5-  
Cash flow per share (Unadj.) Rs3.8256.7-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.6658.1-  
Shares outstanding (eoy) m25.00378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x5.12.5 203.3%   
Avg P/E ratio x-4,712.720.7 -22,801.8%  
P/CF ratio (eoy) x249.612.8 1,943.8%  
Price / Book Value ratio x14.05.0 279.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9881,247,263 1.9%   
No. of employees `0001.625.0 6.2%   
Total wages/salary Rs m1,6050-   
Avg. sales/employee Rs Th3,040.220,038.0 15.2%   
Avg. wages/employee Rs Th1,029.20-   
Avg. net profit/employee Rs Th-3.32,413.9 -0.1%   
INCOME DATA
Net Sales Rs m4,740500,951 0.9%  
Other income Rs m92-2,920 -3.2%   
Total revenues Rs m4,832498,031 1.0%   
Gross profit Rs m-130124,589 -0.1%  
Depreciation Rs m10136,793 0.3%   
Interest Rs m021,608 0.0%   
Profit before tax Rs m-13963,268 -0.2%   
Minority Interest Rs m0-260 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m52,660 0.2%   
Profit after tax Rs m-560,348 -0.0%  
Gross profit margin %-2.724.9 -11.0%  
Effective tax rate %-3.74.2 -87.1%   
Net profit margin %-0.112.0 -0.9%  
BALANCE SHEET DATA
Current assets Rs m2,726440,402 0.6%   
Current liabilities Rs m2,435344,306 0.7%   
Net working cap to sales %6.119.2 32.1%  
Current ratio x1.11.3 87.5%  
Inventory Days Days7478 94.5%  
Debtors Days Days41107 38.0%  
Net fixed assets Rs m1,035115,894 0.9%   
Share capital Rs m5017,715 0.3%   
"Free" reserves Rs m9420-   
Net worth Rs m1,716249,022 0.7%   
Long term debt Rs m0372,014 0.0%   
Total assets Rs m4,1561,003,037 0.4%  
Interest coverage xNM3.9-  
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x1.10.5 228.3%   
Return on assets %-0.18.2 -1.5%  
Return on equity %-0.324.2 -1.2%  
Return on capital %013.6 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Net fx Rs m-960-   
CASH FLOW
From Operations Rs m-865,850 -0.0%  
From Investments Rs m-146-51,931 0.3%  
From Financial Activity Rs m862-17,352 -5.0%  
Net Cashflow Rs m709-3,433 -20.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: FRESENIUS KABI ONCO.  ALKEM LABORATORIES  SUVEN LIFE  BIOCON LTD  FULFORD INDIA  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS